Melanotan I
A melanocortin peptide analogue tied to pigmentation and photoprotection research, and closely related to the approved drug afamelanotide.
Also referenced as: Afamelanotide, Scenesse
Also appears in: Hormone
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Melanotan I crosses your target, drops, or sets a new tracked low—without daily noise.
This peptide maps to at least one regulated medical product or label context in the United States.
Primary research area: Dermal. Also surfaces under Hormone for browsing and discovery.
Afamelanotide, Scenesse
FDA label signal · 23 trials · 121 PubMed results
Melanotan I is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Melanotan I has 14 name-matched clinical trials (highest phase: Phase 3) and 121 PubMed-indexed publications and holds an FDA drug label. 7 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What melanotan I is
Melanotan I refers to a melanocortin peptide analogue better known clinically as afamelanotide. In regulated medicine, afamelanotide is the name that matters more than the older research-market shorthand.
Why it matters
It is one of the clearest examples of a peptide that sits across two different worlds: scientific and clinical development on one side, and aesthetic or tanning-oriented internet discussion on the other.
Regulatory context
Afamelanotide has FDA approval in the United States for a narrow labeled use. That does not mean all products sold under melanotan-style naming are equivalent to an approved medicine.
Practical reading note
This is a good reminder that a familiar peptide-market nickname can hide a very important distinction between approved pharmaceutical use and unregulated cosmetic-market interpretation.